As the most common stem cell type being used within regenerative medicine, there is huge potential for growth within the mesenchymal stem cell (MSC) market. Today, MSCs are the most common stem cell type being used within clinical trials, as well as the most studied stem cell type within the scientific literature. [Read more…]
Mesenchymal Stem Cells (MSCs)
Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).
Market Forces Affecting the Cord Blood and Cord Tissue Industry
Recently released, the “Global Cord Blood & Tissue Banking Industry Report – Market Size, Segmentation, and Forecasts” explores clinical trial market data supporting applications for hematopoietic stem cells (HSCs) from cord blood and mesenchymal stem cells (MSCs) from cord tissue. Within this rapidly evolving marketplace, those who choose to commit to understanding current opportunities and threats will be positioned for a substantial strategic advantage.
Because the global cord blood banking industry has matured substantially over the past few years, new market forces have created both serious threats and novel opportunities. Â [Read more…]
Can New Manufacturing Platform Reduce “Sky High” Costs of Stem Cell Therapies?
The LA Times released a compelling article highlighting the mounting evidence that stem cell treatments will be some of the highest priced treatments within the medical marketplace.  Titled “Sky-high price of new stem cell therapies is a growing concern,” the author Michael Hiltzik explores the often exorbitant costs associated with stem cell procedures.
In a powerful statement that summarizes the author’s position, he writes, “The evidence is already mounting that stem cell and other advanced biologic treatments will be among the most expensive therapies in the medical arsenal.” As examples of expensive cell therapy procedures, Hiltzik cites that Prochymal, a mesenchymal stem cell treatment approved in Canada, can costs as much as $200K, while Provenge, a cell-based vaccine for prostate cancer, can cost nearly $100K to extend a patient’s life by a few months. [Read more…]
MSCs: Why We’re Not There Yet—and What’s Next with Dr. Daniel Kota
In this article, Dr. Daniel Kota provides a mesenchymal stem cell review and explores the future of MSC therapy. Mesenchymal stem cells (MSCs) are multipotent cells that prefer to differentiate into cells of the musculoskeletal system, such as bone, cartilage, muscle and fat cells. However, MSCs can also be induced to become other cell types, as well as exert therapeutic effects by honing to sites of repair and secreting therapeutic agents.
In this article:
MSCs as Essential Raw Materials for Regenerative Medicine Products
MSCs are essential raw materials for many regenerative medicine products, including cell-based therapies, engineered tissues, cosmeceutical preparations, exosome products, and cultured meat. As of today, ClinicalTrials.gov lists at least 2,232 registered clinical trials involving MSCs, targeting a variety of indications ranging from graft vs. host disease (GvHD) to macular degeneration to osteoarthritis. Although ten MSC-based therapeutics have been approved for marketing in other parts of the world, the U.S. FDA is yet to approve an MSC product. Nonetheless, given their therapeutic potential for treating many indications and usage across a variety of applications, researchers believe that MSCs will support many important regenerative medicine advances. [Read more…]
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 59
- Next Page »